150 likes | 392 Views
ALOXI MORE COST EFFECTIVE THAN ZOFRAN!. Presented By: Julie Hoffman, ADN, RN, OCN Sylvia Wentzky, ADN, RN Bon Secours St. Francis Health System Greenville, South Carolina. PURPOSE:.
E N D
ALOXI MORE COST EFFECTIVE THAN ZOFRAN! Presented By: Julie Hoffman, ADN, RN, OCN Sylvia Wentzky, ADN, RN Bon Secours St. Francis Health System Greenville, South Carolina
PURPOSE: The purpose of this Evidence Based Project was to compare the cost effectiveness of two anti-nausea medications: ALOXI and ZOFRAN for patients receiving highly emetogenic chemotherapy regimens, such as Cisplatin.
MATERIALS & METHODOLOGY: • Bon Secours St. Francis Health System Outpatient Infusion Center • Retrospective 3 month chart review • Solid tumor types • 100 adult patients
DATA POINTS COLLECTED: • Gender • Age • Diagnosis • Types of Lung Cancer Treatments • Antiemetics in Cisplatin Protocols
RESULTS: Aloxi: • IV push 1 dose day of chemo • Nursing time -5 minutes • Supplies – needle & syringe Zofran: • IVPB treatment day • 2 extra days of IV fluids and daily Zofran IVPB • Nursing time – 6.5 hours • Supplies – IV tubing ALOXI- 8% Total Cost Savings Increased Patient Satisfaction Decreased Nursing Time ZOFRAN- Lower Patient Satisfaction Increased Clinic Visits Increased Nursing Time
CONCLUSION: The cost analysis demonstrated that selecting Aloxi on Day 1 of the chemotherapy treatment impacted: • Cost • Patient Satisfaction • Nurse Time Limitations of this study included a small sample size, retrospective nature, and selective diagnosis of Lung Cancer.
UPDATE: • Product Availability • Provider Changes & Preferences • Protocol Changes • Dexamethasone 10 mg IVP • Zofran 8 mg IVP • Emend 150 mg IVPB • 3 Month Retrospective Analysis (2014) • 12 Lung Cancer Patients – Cisplatin Treatment • 1 Patient Needed Hydration
REFERENCES: DeLeon, A. (2006, October). Palonosetron (Aloxi): A Second Generation 5HT3 Receptor Antagonist for Chemotherapy-Induced Nausea and Vomiting. Baylor University Medical Center Proceeding, 19(4),413-416. Retrieved from http:///www.medscapecom/viewarticle/512796 Feinberg, B.A., Gilmore, J., Haislip, S., Gondesen, T., Saleh, N., Lenz, W. (2009, February). Data-Driven Medical Decision-Making in Managing Chemotherapy-Induced Nausea and Vomiting, Community Oncology, 62-67. Retrieved from http://www.CommunityOncology.net National Comprehensive Cancer Network. (2011). NCCN Clinical Practice Guilelines in Oncology (NCCN Guidelines) Antiemesis(Version 1.2012). Fort Washington, PA: Ettinger, David S., et al. Tarricone, R., & Girolami, F. (2005). Economic Evaluation of a New Antiemetic Drug – Palonosetron Versus Ondansetron, Clinical Drug Investiation, 25 (9), 597-608 Retrieved from http://www.nci.nlm.nih.gov/pmc/articles/PMC1618755
Bon Secours St. Francis Health System Outpatient Infusion Center Greenville, South Carolina JULIE HOFFMAN, ADN, RN, OCN JULIANA_HOFFMAN @BSHSI.ORG SYLVIA WENTZKY, ADN, RN SYLVIA_WENTZKY@BSHSI.ORG TRACY FASOLINO, PhD, FNP, ACHPN TRACY_FASOLINO@BSHSI.ORG